NewLink Genetics (NLNK) Reaches $6.24 Low on Jun, 8, Akzo Nobel N.V. (ADR) (AKZOY) Covered By 2 Bulls

June 8, 2017 - By Ellis Scott

The stock of NewLink Genetics Corp (NASDAQ:NLNK) reached all time low today, Jun, 8 and still has $5.99 target or 4.00% below today’s $6.24 share price. This indicates more downside for the $175.59M company. This technical setup was reported by Barchart.com. If the $5.99 PT is reached, the company will be worth $7.02 million less. About 7.43 million shares traded or 1128.51% up from the average. NewLink Genetics Corp (NASDAQ:NLNK) has risen 49.90% since June 8, 2016 and is uptrending. It has outperformed by 33.20% the S&P500.

Among 3 analysts covering Akzo Nobel N.V. (OTCMKTS:AKZOY), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Akzo Nobel N.V. had 5 analyst reports since July 27, 2015 according to SRatingsIntel. The firm has “Reduce” rating given on Friday, September 16 by HSBC. As per Monday, July 27, the company rating was downgraded by Citigroup. The company was upgraded on Monday, January 18 by JP Morgan. JP Morgan upgraded Akzo Nobel N.V. (ADR) (OTCMKTS:AKZOY) on Friday, January 15 to “Overweight” rating. As per Tuesday, October 13, the company rating was upgraded by Citigroup. See Akzo Nobel N.V. (ADR) (OTCMKTS:AKZOY) latest ratings:

About 23,959 shares traded. Akzo Nobel N.V. (ADR) (OTCMKTS:AKZOY) has 0.00% since June 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Akzo Nobel N.V. is a paints and coatings company, and a producer of specialty chemicals. The company has market cap of $21.46 billion. The Company’s divisions include Decorative Paints, Performance Coatings, Specialty Chemicals, and Corporate and other. It has a 19.54 P/E ratio. The Decorative Paints segment’s business include Decorative Paints Europe, Middle East and Africa; Decorative Paints Asia, and Decorative Paints Latin America.

Among 3 analysts covering NewLink Genetics (NASDAQ:NLNK), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. NewLink Genetics has $3200 highest and $27 lowest target. $29.67’s average target is 375.48% above currents $6.24 stock price. NewLink Genetics had 4 analyst reports since March 23, 2016 according to SRatingsIntel. The company was upgraded on Thursday, March 30 by SunTrust. The rating was downgraded by SunTrust on Wednesday, May 11 to “Neutral”. The rating was maintained by Cantor Fitzgerald with “Buy” on Sunday, June 4. Robert W. Baird initiated NewLink Genetics Corp (NASDAQ:NLNK) on Wednesday, March 23 with “Outperform” rating.

NewLink Genetics Corporation is a clinical-stage immuno-oncology firm focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The company has market cap of $175.59 million. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. It currently has negative earnings. The Company’s biologic product candidates are based on its HyperAcute Cellular Immunotherapy technology, which is designed to stimulate the human immune system to attack cancer cells.